Abstract
We report the simultaneous development of fulminant hepatic failure, thrombocytopenia and erythroid hypoplasia in a child treated with sulphasalazine. A 12-year-old girl with juvenile rheumatoid arthritis developed fulminant hepatic failure, thrombocytopenia and erythroid hypoplasia, which was confirmed by liver histology and bone marrow examination, 2 weeks after initiation of sulphasalazine therapy. The patient recovered after administration of high doses of intravenous immunoglobulin. this is the first reported case of the concurrent development of these complications associated with sulphasalazine hypersensitivity. The use of intravenous immunoglobulin may have helped in the treatment of this rare adverse effect of sulphasalazine.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Dougados M., vander Linden S., Leirisalo-Repo M. et al. Sulfasalazine in the treatment of spondyloarthropathy: a randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995;38:618–27.
Pinals RS, Kaplan SB, Lawson JG, Hepburn B. Sulfasalazine in rheumatoid arthritis. Arthritis Rheum 1986;29:1427–34.
Imundo LF, Jacobs JC. Sulfasalazine therapy for juvenile rheumatoid arthritis. J Rheumatol 1996;23:360–6.
Ansell BM, Hall JK, Loftus P., et al. A multicenter pilot study of sulfasalazine in juvenile chronic arthritis. Clin Exp Rheumatol 1991;9:201–3.
Ozdogon H, Jurunc M, Deringo B, Yurdakul S, Yuzici H, Sulfasalazine in the treatment of juvenile rheumatoid arthritis: a preliminary open trial. J Rheumatol 1986;13:124–5.
Baum J, Alekseev LS, Brewer EJ, Dolgopolva AV, Mudholkar GS, Patel K. Juvenile rheumatoid arthritis: a comparison of patients from USSR and USA. Arthritis Rheum 1980;23:977–84.
Watkinson G., Sulfasalazine: a review of 40 year's experience. Drugs 1986;32 (suppl):1–11.
Poland GA, Love KR. Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy. Am J Med 1986;81:707–8.
Farr M, Bacon PA, Coppock J, Scott DL, Long term experience of Salazopyrin EN in rheumatoid arthritis. Scand J Rheumatol 1987;64:37–47.
Galindo-Rodriquez G, Avina-Zubita A, Russel AS, Squarez-Almazor ME. Trends in the patterns of practice in the use of first second line therapy in rheumatoid arthristis [abst]. Arthritis Rheum 1994;(suppl)37:s229.
Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS. Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine. Am J Gastroenterol 1986;81205–8.
Haines JD. Hepatotoxicity after treatment with sulfasalzine. Postgrad Med 1986;79:193–7.
Silverman ED, Miller JJ, Bernstein B, Shafai J. Consumption coagulopathy associated with systemic JRA. J Pediatr 1983; 103:872–6.
Cate RHT, Cats A. Toxicity of sulfasalazine in systemic juvenile chronic arthritis. Clin Exp Rheumatol 1991;9:85–8.
Caspi D, Fuchs D, Yarow M. Sulfasalazine induced hepatitis in juvenile rheumatoid arthritis. Ann Rheum Dis 1992;51:275–6.
Stephan JL, Zeller J, Hubert P, Herbelin C, Dayer JM, Prieur AM, Macrophage activation syndrome and rheumatic disease in chilhood: a report of four new cases. Clin Exp Rheumatol 1993;11:451–6.
Jacobs JC, Goin LJ, Hanissian AS. Consumption coagulopathy associated after gold therapy for JRA. J Pediatr 1984;105:674.
Marinos G, Riley J, Painten DM, McCaughan GW. Sulfasalazineinduced fulminant hepatic failure. J Clin Gastroenterol 1992; 14:132–5.
Mihas AA, Goldenberg DJ, Slaughter RL. Sulfasalazine toxic reactions: hepatitis, fever, and skin rash with hypocomplementemia and immune complexes. JAMA 1968;239:2590–1.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Huang, JL., Hung, IJ., Chen, LC. et al. Successfully treated sulphasalazine-Induced fulminant hepatic failure, Thrombocytopenia and Erythroid Hypoplasia with intravenous immunoglobulin. Clin Rheumatol 17, 349–352 (1998). https://doi.org/10.1007/BF01451021
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01451021